Itolizumab provides sustained remission in plaque psoriasis: A 5-year follow-up experience

Clinical and Experimental Dermatology

Volumn 40, Issue 2, 2015, Pages 152-155

  Budamakuntla, Leelavathy ^a   Madaiah, M ^a   Sarvajnamurthy, S ^a   Kapanigowda, S ^a  

^a Bowring and Lady Curzon Hospitals   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ITOLIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INDIA; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY SCALE; PSORIASIS VULGARIS; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84923138527     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12509     Document Type: Article

References (10)

1. Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol 2010; 76: 595-601.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75.
3. Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
4. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 2007; 6: 1205-12.
5. Roque-Navarro L, Mateo C, Lombardero J et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003; 22: 245-57.
6. Krupashankar DS, Dogra S, Kura M et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 2014; 71: 484-92.
7. Nair P, Melarkode R, Rajkumar D et al. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010; 162: 116-30.
8. Christophers E, Segaert S, Milligan G et al. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 2013; 24: 193-8.
9. Kim A. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
10. Kamaria M, Liao W, Koo JY. How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis. Psoriasis Forum 2010; 16: 36-42.